Literature DB >> 30569573

The atypical MAPK ERK3 potently suppresses melanoma cell growth and invasiveness.

Minyi Chen1, Amanda K Myers1, Michael P Markey1, Weiwen Long1.   

Abstract

Mitogen-activated protein kinase 6 (MAPK6) represents an atypical MAPK also known as extracellular signal-regulated kinase 3 (ERK3), which has been shown to play roles in cell motility and metastasis. ERK3 promotes migration and invasion of lung cancer cells and head and neck cancer cells by regulating the expression and/or activity of proteins involved in cancer progression. For instance, ERK3 upregulates matrix metallopeptidases and thereby promotes cancer cell invasiveness, and it phosphorylates tyrosyl-DNA phosphodiesterase 2, thereby enhancing chemoresistance in lung cancer. Here we discovered that ERK3 plays a converse role in melanoma. We observed that BRAF, an oncogenic Ser/Thr kinase, upregulates ERK3 expression levels by increasing both ERK3 messenger RNA levels and protein stability. Interestingly, although BRAF's kinase activity was required for upregulating ERK3 gene transcription, BRAF stabilized ERK3 protein in a kinase-independent fashion. We further demonstrate that ERK3 inhibits the migration, proliferation and colony formation of melanoma cells. In line with this, high level of ERK3 predicted increased survival among patients with melanomas. Taken together, these results indicate that ERK3 acts as a potent suppressor of melanoma cell growth and invasiveness.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  BRAF; cancer; extracellular signal-regulated kinase 3; invasion; melanoma; migration; mitogen-activated protein kinase 6

Mesh:

Substances:

Year:  2018        PMID: 30569573     DOI: 10.1002/jcp.27994

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

1.  ERK3 is transcriptionally upregulated by ∆Np63α and mediates the role of ∆Np63α in suppressing cell migration in non-melanoma skin cancers.

Authors:  Eid S Alshammari; Amjad A Aljagthmi; Andrew J Stacy; Mike Bottomley; H Nicholas Shamma; Madhavi P Kadakia; Weiwen Long
Journal:  BMC Cancer       Date:  2021-02-12       Impact factor: 4.430

2.  Conditional ERK3 overexpression cooperates with PTEN deletion to promote lung adenocarcinoma formation in mice.

Authors:  Sreeram Vallabhaneni; Jian Liu; Marion Morel; Jixin Wang; Francesco J DeMayo; Weiwen Long
Journal:  Mol Oncol       Date:  2021-12-14       Impact factor: 6.603

3.  MAPK6-AKT signaling promotes tumor growth and resistance to mTOR kinase blockade.

Authors:  Qinbo Cai; Wolong Zhou; Wei Wang; Bingning Dong; Dong Han; Tao Shen; Chad J Creighton; David D Moore; Feng Yang
Journal:  Sci Adv       Date:  2021-11-12       Impact factor: 14.136

4.  FBXW7-mediated ERK3 degradation regulates the proliferation of lung cancer cells.

Authors:  Hyun-Jung An; Cheol-Jung Lee; Ga-Eun Lee; Youngwon Choi; Dohyun Jeung; Weidong Chen; Hye Suk Lee; Han Chang Kang; Joo Young Lee; Dae Joon Kim; Jin-Sung Choi; Eun Suh Cho; Jong-Soon Choi; Yong-Yeon Cho
Journal:  Exp Mol Med       Date:  2022-01-12       Impact factor: 12.153

5.  Integrated Analysis of DNA methylation and transcriptome profile to identify key features of age-related macular degeneration.

Authors:  Zhijie Wang; Yinhua Huang; Feixue Chu; Kai Liao; Zekai Cui; Jiansu Chen; Shibo Tang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.